Executive Leadership | 60 Degrees Pharmaceuticals, Inc.

Geoffrey Dow is the CEO, President, and a Director of 60 Degrees Pharmaceuticals, Inc. (60P). He has over 20 years of experience in product development for tropical diseases and a strong publication and patent history. He has 13 years of leadership and advisory experience in the antimalarial drug development program at the Walter Reed Army Institute of Research and the U.S. Army Medical Materiel Development Activity. Dr. Dow co-founded 60P in 2010 and has been instrumental in various projects including securing FDA-regulatory approval for tafenoquine (Arakoda) for malaria prophylaxis, managing post-marketing regulatory commitments, and ensuring the company adheres to GMP, quality, and pharmacovigilance requirements. He has also published several important safety reviews, clinical trials, and non-clinical studies. Dr. Dow's ultimate goal is to develop and secure regulatory approval and commercial success of products for new indications in infectious disease. He holds a B.Sc. (Hons) in Veterinary and Biomedical Science from Murdoch University, Perth, Western Australia (1994), a Ph.D. in Veterinary and Biomedical Science from Murdoch University (2000), and an MBA from the University of Maryland at College Park (2012).

Bryan Smith is the Chief Medical Officer of 60 Degrees Pharmaceuticals, Inc. (60P). He is a medical doctor with expertise in clinical pharmacology, pharmacovigilance, regulatory strategy development, and translational medicine. He has over 30 years of experience in governmental research and leadership and is a retired military colonel. He joined the company in 2016 and works with the senior management team to establish all functional areas, including compliance with laws and regulations and overseeing research and development projects. Dr. Smith is also a Senior Medical Director, Clinical and Regulatory Affairs at Fast-Track Drugs & Biologics, LLC since 2019, where he is responsible for developing clinical development plans, managing clinical and regulatory projects, and designing and writing clinical trial protocols. He has also served as the Chief Medical Officer and member of Amivas LLC, where he established all functional areas required to secure FDA approvals. Additionally, from 2016 to 2019, he was the Principal Medical Consultant at Clinical Network Services, Inc. where he provided medical, clinical pharmacology, regulatory, and translational medicine review, oversight and consultation as requested for over 25 unique clients in a range of activities and tasks for devices, small molecules, and large molecules in a range of therapeutic areas. He holds a Bachelor of Science in General Science, with highest honors, from Oregon State University and a Doctor of Medicine from Uniformed Services University of the Health Sciences.

Kristen Landon serves as Chief Commercial Officer, joining the company in 2024 with more than 29 years of experience building and transforming pharmaceutical brands across start-up and multinational organizations. She has launched and relaunched over a dozen brands across therapeutic areas, including women’s health, infectious disease, dermatology, nephrology, and hematology/oncology. Most recently, she served as Senior Vice President of Marketing and Communications at TherapeuticsMD, where she led the branded portfolio, marketing insights, and corporate communications. She has also held senior leadership positions at companies such as Novartis and Abbott Laboratories. Ms. Landon holds an MBA from Silberman College of Business at Fairleigh Dickinson University and a bachelor’s degree from Kean University.

Tyrone Miller is the Chief Financial Officer at 60 Degrees Pharmaceuticals, Inc. He joined the company in 2014 and has held various roles, advising in areas of financing and business planning. He is also the founder and principal of tax and accounting practice at Miller Tax & Advisory since 2011. Prior to that, he was a senior accountant at Sachs Figurelli, LLC from 2002 to 2011. He is a certified public accountant and received a Bachelor of Business Administration with a concentration in International Business from Emory University in 1996.